1-4 of 4
Halina Urbanska-Rys
Close
Sort by
Journal Articles

Efficacy Of Lenalidomide Treatment In Multiple Myeloma (MM) Patients – a Report of Polish Myeloma Group

Lidia Usnarska-Zubkiewicz, Jakub Debski, MD, Aleksandra K. Butrym, MD, PhD, Wojciech Legiec, Marek Hus, MD, PhD, Anna Dmoszynska, Beata Stella-Holowiecka, MD, Jan M Zaucha, Marcin Rymko, MD, Tigran Torosian, MD, Grzegorz Charlinski, Ewa Lech-Maranda, Artur J. Jurczyszyn, MD, PhD, Halina Urbanska-Rys, Agnieszka Druzd-Sitek, PhD, Kazimierz Kuliczkowski
Journal: Blood
Blood (2013) 122 (21): 3236.
https://doi.org/10.1182/blood.V122.21.3236.3236
Published: 2013
Journal Articles

Polymorphisms in CD31/PECAM-1 and CD38 Genes Are Associated with Susceptibility to Multiple Myeloma

Krzysztof Jamroziak, Zofia Szemraj, Janusz Szemraj, Olga Grzybowska-Izydorczyk, Katarzyna Oszajca, Grazyna Janiszewska, Ewa Balcerczak, Marek Mirowski, Halina Urbanska-Rys, Tadeusz Robak, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 5113.
https://doi.org/10.1182/blood.V112.11.5113.5113
Published: 2008
Journal Articles

Deficiency of Blood Dendritic Cells in Patients with Multiple Myeloma: Possible Significance for Prediction of Response to First Line Treatment.

Piotr Smolewski, Agata Branicka, Barbara Cebula, Halina Urbanska-Rys, Tadeusz Robak
Journal: Blood
Blood (2006) 108 (11): 5032.
https://doi.org/10.1182/blood.V108.11.5032.5032
Published: 2006
Journal Articles

Pharmacogenetic Analysis of Polymorphisms in Pharmacological Pathway of Vincristine, Doxorubicine and Dexamethasone (VAD Regimen) To Predict Response in Patients with Multiple Myeloma.

Krzysztof Jamroziak, MD, PhD, Ewa Balcerczak, PhD, Mariusz Panczyk, Sylwester Piaskowski, Agnieszka Janus, MD, Barbara Cebula, Marek Mirowski, PhD, Piotr Smolewski, MD, PhD, Halina Urbanska-Rys, MD, PhD, Piotr Cichocki, Tadeusz Robak, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 104.
https://doi.org/10.1182/blood.V106.11.104.104
Published: 2005